Table 4.
Risk of extra-intestinal manifestations, colorectal cancer, extra-intestinal cancer and mortality in population based studies.
| Cohort | EIMs | Colorectal Cancer | Extra-digestive cancer | Mortality | |
|---|---|---|---|---|---|
| IBSEN | Peripheral arthritis: 11%, AS: 2.6% by 6y | - | - | Overall: HR 1.1 (95 CI%, 0.9–1.4) | |
| Copenhagen | - | Overall: SMR 1.1 (95% CI, 1.0–1.2), 0.4%, 1.1%, and 2.1% by 10, 20 and 30y | Overall cancer: SMR 0.9 (95% CI, 0.7–1.1) Melanoma: SMR 3.4 (95% CI, 1.4–7.1) | Overall: SIR 1.1 (95% CI, 1.0–1.2) | |
| EC-IBD cohort | 10% by 10y. Articular 8%, Iridocyclitis/Uveitis 0.6%, cutaneous 1.3%, PSC 0.6%. | - | 3.3% by 10 y | Overall: SMR 1.1 (95% CI, 0.9–1.4), Pulmonary diseases: SMR 2.0 (95% CI, 1.0–3.6), Cancer: SMR 1.0 (95% CI, 0.6–1.6), CV: SMR 1.1 (95% CI, 0.7–1.5), GI diseases: SMR 2.0 (95% CI, 0.7–4.7) | |
| Hungary/Veszprem | 17% at 7y | - | NHL: SIR 1.35 (95% CI, 0.34–5.42), NHL in male: SIR 2.4 (95% CI, 0.77–7.47) | 0.6%, 5.4%, 7.5% by 10, 20 and 30y. Disease Duration >1 y: OR 14.3 (95% CI, 1.8–110.5), Chronic continuous disease: OR 6.4 (95% CI, 1.9–21.6), Extensive vs left-sided colitis: OR 5.3 (95% CI, 1.7–16.4), PSC: OR 27.1 (95% CI, 7.9–92.0) | |
| Malmo cohort | - | Overall SIR 2.1 (95% CI, 1.0–4.1) | - | - | |
| Uppsala | - | Overall: SIR 5.7 (95% CI, 4.6–7.0), Proctitis: SIR 1.7 (95% CI, 0.8–3.2), LSC: SIR 2.8 (95% CI, 1.6–4.4), Age <15 y at diag: SIR 4.0 (95% CI, 2.07–7.85), Pancolitis: SIR 14.8 (95% CI, 11.4–18.9) | - | NHL: SIR 1.1 (95% CI, 0.6–1.8), HL: SIR 0.4 (95% CI, 0.0–2.2), Overall leukaemia: SIR 2.3 (95% CI, 1.4–3.7), Acute myeloid leukaemia: SIR 2.5 (95% CI, 1.2–4.8) | - |
| Stockholm County | - | Proctitis: SIR 1.1 (95% CI, 0.7–1.7), LSC: SIR 1.4(95% CI, 1.1–1.9), Pancolitis: SIR 1.4 (95% CI, 1.0–1.9) | Extra-colonic cancer: SMR 1.1 (95% CI, 0.9–1.3), Hepato-Biliary (men): SMR 6.0 (95% CI, 2.8–11.1), Pulmonary: SMR 0.3 (95% CI, 0.1–0.9) | Overall: SMR 1.4 (95% CI, 1.2–1.5), Cancer: SMR 1.2 (95% CI, 0.9–1.6), CRC: SMR 2.9 (95 CI%, 1.6–4.7), Respiratory disease: SMR 1.9 (95% CI, 1.1–2.9), Liver disease: SMR 4.8 (95% CI, 2.1–9.5) | |
| South-Limburg | 7% at 7y | - | - | Overall: SMR 0.9 (95% CI, 0.7–1.2), GI causes: SMR 3.4 (95% CI, 1.4–7.0), GI causes (Women): SMR 8.6 (95% CI, 2.8–20.0), GI causes (<19y) SMR 537.3 (95% CI, 7.0–2989) | |
| Olmsted | Cumulative incidence of SpA: 14% at 20y | Overall SIR 1.1 (95% CI, 0.4–2.4), Proctitis SIR 0 (95% CI, 0.0–3.5), Pancolitis SIR 2.4 (95% CI, 0.6–6.0) | Overall cancer: 5% by 10 years, Overall cancer: SIR 1.1 (95% CI, 0.8–1.4), Overall cancer (women): SIR 1.6 (95% CI, 1.1–2.3), Overall cancer (men): SIR 0.9 (95% CI, 0.6–1.2), Hemato malignant tumors: SIR 2.7 (95% CI, 1.2–5.3), Melanoma: SIR 2.0 (95% CI, 0.7–4.4), Hepatobiliary: SIR 11.4 (95% CI, 2.4–33.2), Lung: SIR 0.3 (95% CI, 0.1–0.9) | Overall: SMR 0.8 (95% CI, 0.6–1.0), GI diseases: SMR 2.0 (95% CI, 0.8–4.4), GI cancer: SMR 2.2 (95% CI, 0.7–5.2), CV Death: SMR 0.6 (95% CI, 0.4–0.9) | |
| EPICOM | - | - | - | 0.3% at 1y | |
| North Jutland County | - | SIR 0.8 (95% CI, 0.5–1.4). Young age at diagnosis SIR 17.1 (95% CI, 0.4–95.1) | Overall cancer: SIR 1.1 (95 % CI, 0.9–1.2), Prostate: SIR 1.8 (95% CI, 1.1–2.7) | - | |
| Florence | - | Overall: SIR 1.7 (95% CI, 0.8–3.2), Extensive colitis: SIR 3.1 (95% CI, 1.5–5.8) | Overall cancer: SIR 1.0 (95% CI, 0.7–1.3), Respiratory tract: SIR 0.2 (95% CI, 0.0–0.8) | Overall: SMR 0.7 (95% CI, 0.6–0.9), CV: SMR 0.7 (95% CI, 0.5–1.0), Overall cancer: SMR 0.7 (95% CI, 0.5–1.0), Lung cancer mortality: SMR 0.3 (95% CI, 0.1–1.0), CRC: SMR 1.3 (95% CI, 0.3–3.2), GI disease: SMR 1.6 (95% CI, 0.8–2.8) | |
| Area of Tampere University Hospital | - | Overall: SIR 2.0 (95% CI, 1.1–3.3), Proctitis: SIR 0.0 (CI 95%, 0.0–2.8), Left sided colitis: SIR 1.8 (95% CI, 0.7–3.8), Pancolitis: SIR3.1 (95% CI, 1.5–5.8) | - | Overall: SMR 0.9 (95% CI, 0.8–1.1), CV: SMR 1.0 (95% CI, 0.8–1.4), CRC: SMR 1.8 (95% CI, 0.7–3.7) | |
Abbreviations: Dis, disease; Diag, diagnosis; AS, Ankylosing Spondylitis, SpA, Spondylarthropathy; EN, Erythema Nodosum; PG, Pyoderma Gangrenosum; PSC, Primary Sclerosing Cholangitis; SIR; Standardized Incidence Ratio; SMR; Standardized Mortality Ratio; OR, Odds Ratio; HR, Hazard Ratio; PSC, Primary sclerosing cholangitis; NHK, Non Hodgkin Lymphoma; HL, Hodgkin Lymphoma; LSC, Left Side Colitis; CV, Cardiovascular; GI, Gastrointestinal.